Gentileschi, S.; Cannistrà , C.; Gaggiano, C.; Damiani, A.; Carli, L.; Benucci, M.; Cantini, F.; Niccoli, L.; Vitale, A.; Baldi, C.;
et al. Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers. J. Pers. Med. 2024, 14, 1105.
https://doi.org/10.3390/jpm14111105
AMA Style
Gentileschi S, Cannistrà C, Gaggiano C, Damiani A, Carli L, Benucci M, Cantini F, Niccoli L, Vitale A, Baldi C,
et al. Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers. Journal of Personalized Medicine. 2024; 14(11):1105.
https://doi.org/10.3390/jpm14111105
Chicago/Turabian Style
Gentileschi, Stefano, Carlo Cannistrà , Carla Gaggiano, Arianna Damiani, Linda Carli, Maurizio Benucci, Fabrizio Cantini, Laura Niccoli, Antonio Vitale, Caterina Baldi,
and et al. 2024. "Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers" Journal of Personalized Medicine 14, no. 11: 1105.
https://doi.org/10.3390/jpm14111105
APA Style
Gentileschi, S., Cannistrà , C., Gaggiano, C., Damiani, A., Carli, L., Benucci, M., Cantini, F., Niccoli, L., Vitale, A., Baldi, C., Delle Sedie, A., Cantarini, L., Mosca, M., Frediani, B., & Guiducci, S.
(2024). Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers. Journal of Personalized Medicine, 14(11), 1105.
https://doi.org/10.3390/jpm14111105
